KLK3 and prostate cancer: G114-particles (∼950 ​nm in size) loaded in MSCs were capable of sustained release of G114 as an intact prodrug for 7 days and selective activation of cell death in the prostate specific antigen (PSA)-secreting prostate cancer cell line LNCaP in vitro and tumor growth inhibition in vivo [109].